Azelis Group NV/€AZE

06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Azelis Group NV

Azelis Group NV operates within the specialty chemicals and food ingredients industry, focusing on the distribution of innovative chemical and food ingredients. The company serves various sectors, including personal care, food and health, animal nutrition, home care, and industrial applications. Established in 2001, Azelis is headquartered in Antwerp, Belgium, and has developed a strong global presence with operations in over 50 countries. Its strategic positioning benefits from a network of laboratories and technical centers, enabling tailored solutions and value-added services for customers. Azelis’s competitive strength lies in its ability to leverage deep local market insights while maintaining close relationships with key suppliers.

Ticker

€AZE

Primary listing

BSE

Employees

4,321

Azelis Group NV Metrics

BasicAdvanced
€2.3B
14.04
€0.69
0.54
€0.16
1.63%

Bulls say / Bears say

Free cash flow increased by 34.3% to €293 million in Q3 2025, underscoring Azelis’s strong cash conversion and disciplined working capital management. (Investing.com)
Revenue rose 2% year-on-year to €3.2 billion in Q3 2025, demonstrating the resilience of Azelis’s asset-light distribution model amid geopolitical and tariff headwinds. (Investing.com)
Fitch affirmed Azelis’s ‘BB+’ issuer default rating with a Stable Outlook, citing the company’s resilient business model and an expectation to maintain EBITDA net leverage below 3.5x through 2025-28. (MarketScreener)
Kepler Cheuvreux downgraded Azelis to Hold on August 7, 2025, citing concerns over the company’s elevated leverage and a discounted peer-relative valuation. (Investing.com)
UBS cut Azelis’s rating to Neutral and lowered its price target to €12.5, highlighting deteriorating demand conditions, tariff impacts, oversupply, and a net debt/EBITDA ratio of 3.1x above the company’s target range. (Investing.com)
Berenberg downgraded Azelis to Hold on June 5, 2025, pointing to near-3x leverage, private equity ownership, and weaker Q1 results that constrain near-term earnings and valuation upside. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €AZE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs